Krystal Biotech Inc is a biotechnology company focused on developing innovative gene therapies to treat debilitating skin and rare diseases. The company harnesses its proprietary, skin-targeted gene delivery platform to create treatments aimed at addressing the underlying genetic causes of these conditions. By advancing its pipeline of product candidates, Krystal Biotech seeks to provide transformative therapies that can improve the quality of life for patients affected by various skin disorders and other genetic conditions. The company's commitment to research and development ensures a strong focus on scientific excellence and innovative solutions in the field of gene therapy. Read More
Krystal Biotech (NASDAQ:KRYS) reported second-quarter 2026 net revenue of $119.2 million from global sales of VYJUVEK, up 24% from $96 million in the prior-year period, as the company expanded treatment access for patients with dystrophic epidermolysis bullosa, or DEB, in the United States and overs
Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (Nasdaq: KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025
